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Abstract Intramyocardial bone marrow cell injection is
currently being investigated as a new therapeutic option for
the treatment of chronic myocardial ischemia. Experimental
studies and early phase clinical trials established a favorable
safety profile of this approach and suggested that bone
marrow cell injection was associated with clinical and
functional improvements. Recently, a randomized, double-
blind, placebo-controlled trial demonstrated that intramyo-
cardial bone marrow cell injection was associated with
beneficial effects on myocardial perfusion and anginal
symptoms. However, the mechanisms by which bone
marrow cells may improve myocardial perfusion are only
partially understood, and several issues remain to be
addressed. This review aims to provide a summary of the
current experience with bone marrow cell therapy as a
novel treatment option for patients with chronic myocardial
ischemia. Therefore, the most frequently used cell types
will be reviewed along with the mechanisms through which
bone marrow cells may improve myocardial perfusion and
function. In addition, possible routes of delivery are
compared, and the results of currently available experimen-
tal and clinical studies are discussed.
Keywords Cell therapy.Myocardial ischemia.Bone
marrow cells.Intramyocardial injection
Introduction
Coronary artery disease is a major cause of mortality and
morbidity in the western world. Despite successive revas-
cularization procedures, a large number of patients end up
with end-stage coronary artery disease, not amenable for
mechanical revascularization. These patients often have
stress-inducible myocardial ischemia, resulting in disabling
complaints of angina, refractory to medical treatment [1].
Intramyocardial bone marrow cell injection is currently
under investigation as a new therapeutic option for these
patients. This treatment aims to improve myocardial
perfusion and contractile function (and decrease anginal
complaints) through administration of bone marrow cells
into ischemic myocardium.
Although some large multicenter trials have investigated
bone marrow cell therapy in patients with acute myocardial
infarction, only small- and medium-sized studies have been
conducted in patients with chronic myocardial ischemia. In
a recently published randomized trial, we documented
clinical and functional improvement after bone marrow cell
injection in patients with chronic myocardial ischemia [2].
However, the mechanisms by which bone marrow cells
may improve myocardial perfusion are not fully under-
stood. Moreover, questions remain with regard to the
optimal cell type, cell dose, and delivery route.
This review will focus on the clinical applicability of
bone marrow cell therapy as a new therapeutic option for
chronic myocardial ischemia and will describe the most
frequently used cell types for treatment of myocardial
ischemia, as well as the possible modes of cell delivery.
Furthermore, an overview is provided of the experimental
and clinical studies that investigated bone marrow cell
administration for the treatment of chronic myocardial
ischemia.
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Hematopoietic Stem Cells
Hematopoietic stem cells (HSC), commonly identified by
CD34, CD45, and/or CD133 surface expression, comprise
<0.01% of the total bone marrow cell population and 1–3%
of the bone marrow mononuclear cell fraction, with very
small amounts of HSC circulating in peripheral blood
(<0.1% of circulating leukocytes). Hematopoietic stem cells
have been used for decades for cell transplantation in
hematological diseases because of their ability to differen-
tiate to all types of blood cells. In 2001, the concept was
introduced that HSC could transdifferentiate into cardio-
myocytes, resulting in substantial de novo myocardium
formation after myocardial infarction [3]. Since different
animal studies yielded discrepant results [4–8], the ability
of bone marrow-derived cells to differentiate into cardiac
cell types remains subject of controversy [9]. Nonetheless,
in the majority of studies, HSC injection was associated
with improvements in cardiac function and attenuation of
post-infarct remodeling. Since myocardial engraftment of
HSC was transient [6], it has been suggested that these
functional improvements may be attributable to paracrine
effects. Experimental studies demonstrated that CD34+
cells may exert paracrine effects resulting in stimulation
of angiogenesis [10], inhibition of apoptosis [11], recruit-
ment of resident cardiac progenitor cells and changing
extracellular matrix composition [12]. Because the CD34+
cell fraction is overlapping with other cell types such as
endothelial progenitor cells, it is difficult to determine the
exact role of HSC and HSC subpopulations in improving
myocardial function.
Endothelial Progenitor Cells
Originally, endothelial progenitor cells (EPC) were defined by
the expression of the hematopoietic stem cell markers CD34,
CD45, or CD133 and the co-expression of vascular endothelial
growth factor receptor-2 [13]. These cells comprise 0.1% to
0.4% of mononuclear cells in the bone marrow [14]b u tc a n
also be detected in peripheral blood at very low concentrations
(<0.1% of mononuclear cell fraction) [15]. Characterized by
high proliferative capacity, these EPC are considered to be
circulating angioblasts, since they have the ability to
incorporate into foci of neovascularization, differentiate into
endothelial cells, and thus, contribute to angiogenesis [16, 17].
However, in culture-expanded EPC, another CD34−/CD14+
cell population expressing monocyte markers was identified.
These “early” EPC have relatively low proliferative capacity
and are supposed to stimulate angiogenesis predominantly by
secreting pro-angiogenic factors [18, 19].
Of note, EPC numbers and function have been shown to
be inversely related to risk factors for vascular disease [20]
and to be reduced in patients with coronary artery disease
[21] Moreover, circulating EPC numbers have been
identified as an independent predictor of cardiovascular
events in patients with coronary artery disease [15, 22]. On
the other hand, EPC numbers and function may improve
after medical treatment, such as statin treatment [23–25]o r
non-pharmacological interventions [26, 27]. These obser-
vations suggest an important role for EPC in vascular
homeostasis and thus, emphasize the great potential of EPC
for vascular regeneration. Nonetheless, therapeutic useful-
ness of EPC treatment may be hampered by reduced
numbers and angiogenic potential in patients with coronary
artery disease.
Mesenchymal Stem Cells
Mesenchymal stem cells (MSC) are multipotent cells that
can differentiate amongst others into osteocytes, chondro-
cytes, and adipocytes. Although MSC represent only
0.001% to 0.01% of the nucleated cells in the bone marrow,
they can easily be isolated and efficiently be expanded
because of their extensive proliferative capacity. It is
uncertain whether MSC are present in peripheral blood
under physiological circumstances [28].
In several studies, differentiation of MSC into a
cardiomyocyte-like phenotype has been observed after
intramyocardial injection [29, 30]. On the contrary, other
studies observed improvements in left ventricular (LV)
function in the absence of cardiomyogenic differentiation
[31–33]. Therefore, the ability of MSC to differentiate into
cardiomyocytes in vivo is still subject of debate, and other
mechanisms have been proposed to account for the
observed improvements in LV function. In particular, it
has been suggested that MSC may promote neoangio-
genesis by differentiation in endothelial cells and smooth
muscle cells [31, 32] and secretion of pro-angiogenic
cytokines [34]. Moreover, MSC have immunomodulatory
effects and have the ability to reduce inflammation by
inhibiting T cell proliferation and shifting cytokine
balance, and may thus beneficially affect post-infarct LV
remodeling [35].
Because of the favorable biologic profile of MSC,
combined with their accessibility for harvest and propensity
to propagate in culture, MSC are promising candidate for
therapeutic use for cardiac purposes. Since MSC possess
low immunogenicity, they could be used allogeneically [36]
and are theoretically suitable “off the shelf” therapeutic use.
However, this may be hindered by induction of an
immunological response in the recipient of these allogeneic
cells, leading to sensitization and accelerated elimination of
the injected cells, as previously suggested [37].
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Because studies comparing the capacities of these different
cell types are scarce, many investigators have chosen a
pragmatic approach by using bone marrow-derived mono-
nuclear cells (BMMC), also referred to as “unfractionated”
bone marrow cells. The mononuclear cell fraction com-
prises a heterogeneous cell population including HSCs,
EPCs, and MSCs, but also several rare populations such as
side population cells and multipotent adult progenitor cells.
The bone marrow provides an easily accessible, renewable,
and autologous source of BMMC and no extensive ex vivo
manipulation is required, facilitating clinical introduction of
this technique. Nonetheless, besides these practical advan-
tages, BMMC may be preferred above selected cell types
because of other reasons. For example, in a comparative
experimental study, van der Bogt et al. observed that
BMMC exhibited a more favorable survival pattern of
BMMC as compared to MSC and skeletal myoblasts,
resulting in reduced LV remodeling after myocardial
infarction [38]. In addition, it has been suggested that
other, non-progenitor cells present in BMMC, such as
macrophages, may contribute to improvement of cardiac
function by accelerating vascularization [39]. Therefore, it
may be hypothesized that combinations of bone marrow-
derived cells rather than selected cellular subfractions are
more suitable and effective for cardiac cell therapy, as the
interplay between the cell types that also occurs in their
natural environment in the bone marrow may be necessary
for their optimal efficacy in cardiac repair.
Routes of Cell Delivery
In patients with chronic myocardial ischemia, direct
intramyocardial injection is preferred above intracoronary
transfusion and intravenous transfusion, since intramyo-
cardial injection allows delivery of cells in ischemic
myocardial territories with ano c c l u d e dc o r o n a r ya r t e r y .
Currently, intramyocardial injection has been described
using trans-epicardial injection, trans-endocardial injec-
tion, and trans-venous injection.
Trans-epicardial injection is usually performed during
open heart surgery. During the procedure, the myocardium
is visualized and cell injections can be targeted into
infarcted areas or ischemic myocardium. Because of its
invasiveness, trans-epicardial injection is not performed as
a stand-alone procedure and is usually performed as an
adjunct to coronary artery bypass grafting. Therefore, it
may be difficult to assess the efficacy of cell injection since
conventional revascularization is performed simultaneously.
Trans-endocardial injection is most often performed with
the use of an endoventricular catheter guided by a three-
dimensional (3D) electromechanical mapping system,
allowing direct injection of therapeutic cells into the
myocardium. Using this non-fluoroscopic, 3D electrome-
chanical mapping system mapping system, viable, hiber-
nating, and infarcted myocardium can be accurately
distinguished [40]. As such, the viability of a myocardial
site can be assessed before each injection. After acquiring a
stable catheter position perpendicular to the myocardial
wall, a needle can be extended from the catheter tip and
therapeutic cells can be injected in the myocardium. The
ability to assess the viability of a potential injection site
before injection is a valuable advantage of trans-
endocardial injection, allowing accurate targeting of thera-
peutic cells into ischemic myocardium or the infarct border
zone [41]. Although the risk of endocardial damage and
ventricular perforation are considered as potential disad-
vantages of this approach, more than 100 patients with
chronic myocardial ischemia have been successfully
injected using a 3D electromechanical mapping system [2,
42–45], with only one patient reported to have pericardial
effusion [2]. In recently infarcted myocardium, however,
trans-endocardial injection may pose a larger risk, although
a recent study did not observe periprocedural events during
trans-endocardial bone marrow cell injection 10 days after
myocardial infarction [46].
A small number of studies have investigated trans-
venous intramyocardial injection technique, involving
injection of therapeutic cells through the coronary veins
into the myocardium [47–50]. For this purpose, a catheter
system with an extendable needle and an ultrasound tip for
guidance is used. Since only right-sided catheterization is
necessary and no electromechanical mapping is performed,
the trans-venous technique may be advantageous with
regard to procedural time and procedural-related cost. On
the contrary, the insertion of the catheter to the cardiac
venous system may cause irreversible damage to the
coronary veins, and incorrect positioning of the needle
may result in perforation of the venous wall, leading to
pericardial hemorrhage. Therefore, larger studies are war-
ranted to investigate the safety and feasibility of this
approach.
The optimal cell dose and delivery route are still under
investigation. For direct intramyocardial injection, it has
been demonstrated that a larger cell dose results in retention
of a larger number of cells [51]. Nonetheless, delivery of
large amounts of cells may theoretically not always be safe
and feasible, although no complications have been ob-
served after intramyocardial delivery. Therefore, optimal
cell dose for direct intramyocardial injection, trans-
endocardial injection, and trans-venous intramyocardial
injection remains to be determined.
Cell engraftment is not only influenced by the route of
delivery, but is also dependent of cell type and myocardial
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was associated with engraftment rates ranging from 25%
after 48 h to 0.3–3.5% at 6 weeks [51–54]. Trans-
endocardial intramyocardial injection resulted in retention
of 11.3±3% of the injected cells 1 h after injection of
peripheral blood-derived mononuclear cells in a porcine
model of myocardial infarction [55]. In another experimen-
tal study, engraftment of 5.8±1.1% of the injected cells was
demonstrated 10 days after trans-endocardial injection of
reporter gene transfected MSC in recently infarcted pig
myocardium. Limited data are currently available on cell
retention after trans-venous intramyocardial injection, al-
though an initial study demonstrated effective injection and
cell engraftment in porcine myocardium after injection of
MSC [50].
Since all experimental studies investigating cell fate have
been performed using models of myocardial infarction, no
data are available about cell engraftment in chronic
ischemic myocardium. Until now, most investigators have
chosen the trans-endocardial delivery route for the treat-
ment of myocardial ischemia because of its limited
invasiveness and favorable safety profile. Nonetheless,
additional research is warranted to further explore the fate
of the injected cells in chronic ischemic myocardium in
relation to the different routes of delivery. Promising
strategies to improve cell retention and engraftment are
under investigation and may be of crucial importance to
improve the functional benefits of stem cell therapy [56].
Experimental Studies
The majority of experimental studies investigating the
effects of cell therapy have been performed in animal
models of acute myocardial infarction. Only a minority of
studies has been conducted using animal models of chronic
myocardial ischemia, such as ameroid constrictor place-
ment in the left anterior descending or circumflex coronary
artery. Similar to studies in animal models of acute
myocardial infarction models, comparison of different
studies is difficult, since differences exist in cell isolation
methods, cell dose, timing of delivery, and the character-
istics of the animal model. Nonetheless, the results of these
studies lead to the concept that bone marrow cell injection
in ischemic myocardium may improve myocardial perfu-
sion and function by stimulating angiogenesis, through
differentiation into endothelial cells and smooth muscle
cells, and secretion of pro-angiogenic cytokines (Fig. 1).
For example, the study of Kawamoto et al. reported
macroscopic collateral formation and increased capillary
density after intramyocardial cell injection in a swine
m o d e lo fm y o c a r d i a li s c h e m i a[ 57]. In this study,
adhesive CD 31+ cells isolated from peripheral blood
were injected in ischemic myocardium using a 3D
electromechanical mapping system, resulting in enhanced
neovascularization that was accompanied by improve-
ments in LV function. In line with these results, Silva et
al. described increased capillary density and improved LV
function after MSC injection using a canine ischemia
model [31]. In addition, injected MSC were found to
colocalize with endothelial cells and smooth muscle cells
but not with cardiomyocytes, suggesting differentiation of
MSC into these in vascular cell types.
In contrast, Fuchs et al. observed improved myocar-
dial perfusion and enhanced contractility in the absence
of microscopic or macroscopic collateral formation [58].
In this study, freshly aspirated, unselected bone marrow
cells were injected into ischemic myocardium of pigs
using a 3D electromechanical mapping system. Of note,
this study demonstrated that the injected bone marrow
cells secreted angiogenic factors, which induced in vitro
endothelial cell proliferation, suggesting that the observed
improvements were mainly the result of paracrine function
of the injected cells, possibly leading to changes in
vascular diameters or decreased resistance to collateral
flow. Importantly, since freshly aspirated, non-enriched
bone marrow was injected in this study, the absence of
collateral formation may be attributable to lower dose of
progenitor cells as compared to studies using bone marrow
mononuclear cells or enriched cell populations. Moreover,
red blood cell contamination may have reduced progenitor
cell function [59].
In a study focusing on the functional results of bone
marrow cell injection, Schneider et al. compared intra-
myocardial injection of BMMC and MSC in a porcine
model of chronic myocardial ischemia [60]. In all cell-
treated animals, improved LV function, reduced fibrosis,
and increased vascular density were observed, with none of
both cell types being superior. In addition, using strain rate
imaging, a favorable effect on diastolic function was
observed, as evidenced by improved parameters of filling
pressure and myocardial relaxation.
Importantly, none of the animal studies did pose any
concerns with regard to the safety of intramyocardial bone
marrow cell injection for chronic myocardial ischemia. Of
note, no excessive necrosis was observed at the sites of
intramyocardial injection [57, 58]. Furthermore, in a
porcine model of chronic myocardial ischemia, Krause et
al. demonstrated that 3D electromechanical mapping-
guided injection of both bone marrow-derived mononuclear
cells and MSC into ischemic myocardium did not increase
fragmentation and duration of endocardial electrograms
[61]. These findings suggest that injection of either bone
marrow cells or MSC is not likely to create a substrate for
arrhythmias and confirms observations from early clinical
studies [62].
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Supported by encouraging preclinical data and an unmet
clinical need, several clinical studies were initiated to
investigate intramyocardial bone marrow cell injection as
a novel therapeutic option for the treatment of chronic
myocardial ischemia. In these studies, patients with
refractory angina ineligible for conventional revasculariza-
tion were treated with trans-endocardial bone marrow cell
injection, performed during cardiac catheterization with the
use of electromechanical mapping. In Table 1, a summary
of these studies is provided. Four studies included patients
with angina [42, 43, 63, 64], whereas one study included
patients with heart failure [44]. The combined experience of
these studies indicated that bone marrow cell injection is a
safe and feasible treatment in patients with chronic
myocardial ischemia. However, one patient in the study of
Perin et al. died suddenly at 14 weeks follow-up. Although
sudden cardiac death is a relatively a common complication
of ischemic heart failure, a cell-related cause of this event
could not be ruled out. Of note, two studies demonstrated
that intramyocardial bone marrow cell injection was not
associated with progression of atherosclerosis [65] and did
not alter the electrophysiological properties of the injected
myocardium [62].
Importantly, most of these initial clinical studies reported
improvements in myocardial perfusion, LV function and
anginal complaints after bone marrow cell injection. Since
only preliminary conclusions could be drawn from these
nonrandomized studies, several randomized trials were
initiated to assess the efficacy of intramyocardial bone
marrow cell injection.
In a small-sized randomized trial, Losordo et al.
documented the feasibility and safety of intramyocardial
injection of granulocyte colony-stimulating factor (G-CSF)-
mobilized CD34+ stem cells [66]. No significant effect on
angina frequency, exercise time, or Canadian Cardiovascu-
lar Society (CCS) score was observed, which may have
been due to underpowering for these outcomes. In the
PROTECT-CAD trial, Tse et al. evaluated the effect of
intramyocardial bone marrow cell injection on myocardial
perfusion, LV function and clinical parameters in 28
patients with myocardial ischemia [45]. Patients were
randomized in a 1:1:1 ratio to receive low dose bone
marrow cells (n=9), high dose bone marrow cells (n=10),
or placebo solution (n=9). Diabetes and previous percuta-
neous coronary intervention were more frequent in the
placebo group than in the bone marrow cell groups,
suggesting that baseline risks were not completely balanced
between the groups. Although bone marrow cell injection
was associated with a modest increase in exercise capacity
and LV ejection fraction, no significant treatment effect on
CCS class was observed, indicating no effect of bone
marrow cell injection on anginal complaints. Moreover, the
changes in myocardial perfusion did not differ significantly
Fig. 1 Potential mechanisms by
which bone marrow cells may
improve myocardial perfusion
and anginal symptoms
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J. of Cardiovasc. Trans. Res. (2011) 4:182–191 187between the (pooled) cell group and the placebo group.
Only when post hoc analysis was performed, a significant
improvement in myocardial perfusion was observed in bone
marrow cell-injected myocardial regions.
In a recently published randomized, double-blind,
placebo-controlled trial from our group, 50 patients were
randomly assigned to intramyocardial injection of either
BMMC or placebo solution [2]. In this study, bone marrow
cell injection was associated with a significant improve-
ment in myocardial perfusion, as evidenced by a decrease
in ischemic myocardial segments from 3.9±1.8 at baseline
to 1.5±1.5 at 3 months follow-up (treatment effect −2.4,
95% CI −2.9, −1.9 vs. −0.8, 95% CI −1.2, −0.3, P<0.001).
Single-photon emission computed tomography images from
a representative patient from this study are shown in Fig. 2.
Furthermore, magnetic resonance imaging revealed a modest
but significant improvement in LV ejection fraction. More-
over, these improvements in myocardial perfusion and
function were accompanied by a significant improvement in
CCS class and an increase in quality of life. Thus, in this
study, more pronounced improvements in myocardial perfu-
sionandanginalcomplaintswereobservedafter bonemarrow
cell injection as compared to the PROTECT-CAD study.
Sinceasignificantlylargeramountofcellswasinjectedinthis
study (98  7  106 as compared with 42  28  106 in the
PROTECT-CAD study), it may be hypothesized that these
differences are related to a dose–response relationship, as has
been suggested in a recent trial in patients with acute
myocardial infarction [67]. Furthermore, group size was
substantially larger in this study as compared with the
PROTECT-CAD study and baseline characteristics were
well balanced between the groups, which may potentially
explain the observed differences.
Preliminary results of a large, multicenter randomized
trial document a beneficial effect of intramyocardial
injection of G-CSF-mobilized CD34+ cells on exercise
time and anginal complaints [68]. However, the final results
of this trial, including the effects on myocardial perfusion
and anginal complaints, remain to be presented.
Summary and Potential Directions for Future Research
Intramyocardial bone marrow cell injection has emerged as
a promising new treatment strategy for the treatment of
patients with chronic myocardial ischemia. Nonrandomized
clinical studies indicated the safety and feasibility of this
approach, and suggested a beneficial effect on clinical and
functional parameters. Until now, one medium-sized ran-
domized trial has confirmed these findings by demonstrat-
ing significant improvement in myocardial perfusion and
anginal complaints as compared to placebo treatment. In
addition, preliminary results from a large multicenter study
investigating injection of G-CSF-mobilized CD34+ stem
cells support the concept that bone marrow cell injection is
an effective treatment for patients with refractory angina
without option for conventional revascularization.
In the near future, the effectiveness of bone marrow cell
injection should be further explored. For example, future
studies will have to investigate whether the observed
improvements are sustained over longer periods of follow-
up. In addition, clinical trials such as the ongoing FOCUS
trial [69] will point out whether effective treatment of
myocardial ischemia by intramyocardial bone marrow cell
injection can be extended to patients with LV dysfunction.
Furthermore, predictors of response may be identified,
since these may provide directions for future experimental
research and contribute to patient selection. Finally, future
studies will have to assess whether the observed improve-
ments in anginal complaints and myocardial perfusion
result in improved survival and/or a reduced number of
hospitalizations, because such data are crucial to determine
the cost-effectiveness of this novel treatment modality in its
current form.
Further innovations which may possibly enhance the
efficacy of cell therapy are under investigation. Besides
identification of promising cell types [70], strategies have
been developed to augment cell engraftment and function
[56, 71, 72], such as pharmacologic stimulation [73, 74]o r
ischemic preconditioning [75]. Furthermore, the combina-
tion of gene therapy and cell therapy holds great potential.
Fig. 2 SPECT images (horizontal short-axis projections) from a
representative patient from the study of van Ramshorst et al. 99mTc-
Tetrofosmin SPECT shows stress-induced ischemia at baseline in the
inferior wall (arrowheads). At 3 months follow-up, the ischemia in the
inferior wall has resolved
188 J. of Cardiovasc. Trans. Res. (2011) 4:182–191Transduction of genes into stem cells may improve
survival, retention, and angiogenic function. On the other
hand, stem cells may be used as vectors for local drug
delivery. Finally, the use of biomaterials is a promising
technique to improve cell retention and survival, which
may contribute to the optimization of delivery techniques
[76, 77]. It is hoped that these innovations will result in
effective cell-based treatment strategies for a variety of
diseases, extending the spectrum of therapeutic options for
patients who have exhausted conventional therapies.
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